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Fibroblast growth factor-23 (FGF23), a regulator of mineral
metabolism, has been linked to cardiovascular disease in
chronic kidney disease. As community-based data of the
longitudinal association between FGF23 and cardiovascular
events are lacking, we investigated a possible relationship in
727 men of the Uppsala Longitudinal Study of Adult Men
population-based cohort (mean age 77 years). During a
median follow-up of 9.7 years, 110 participants died of
cardiovascular causes. In Cox regression models adjusted for
age and established cardiovascular risk factors, higher serum
FGF23 was associated with a significantly increased risk for
cardiovascular mortality (hazard ratio (HR) per increased s.d.
of 1.36). This relationship remained significant, albeit
attenuated, after adjustment for glomerular filtration rate
(GFR) (HR 1.21). FGF23 was also associated with all-cause
mortality, although the association was weaker than that
with cardiovascular mortality, and it was nonsignificant in
fully adjusted multivariate models. Spline analysis suggested
a log-linear relationship between FGF23 and outcome.
Participants with a combination of high FGF23 (460pg/ml),
low GFR (o60ml/min), and micro-/macro-albuminuria
(albumin/creatinine ratio above 3mg/ml) had an almost
eightfold increased risk compared with participants without
these abnormalities. Thus, a higher FGF23 level is associated
with an increased cardiovascular mortality risk in the
community. Clinical trials are needed to determine whether
FGF23 is a modifiable risk factor.
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There is growing recognition of the causal interplay between
a disordered mineral metabolism and development of
cardiovascular disease.1 The clinical importance of this
relationship is particularly emphasized in patients with
chronic kidney disease (CKD), who suffer from a marked
increased cardiovascular risk paralleled by overt changes in
mineral metabolism such as hyperphosphatemia, elevated
parathyroid hormone (PTH), and vitamin D deficiency.2
However, recent studies also favor that subtle changes
of these parameters, within the defined normal range
for healthy individuals, are independent cardiovascular risk
factors.3–5
Fibroblast growth factor-23 (FGF23) is a circulating
hormone that has a pivotal role in the homeostatic
control of mineral metabolism.6 FGF23 reduces serum
phosphate level by blocking renal phosphate uptake from
the urinary filtrate and indirectly lowers serum calcium
through its inhibitory action on systemic vitamin D and
PTH concentrations.7–10 FGF23 has also been suggested
to be directly involved in pathological processes in the
vasculature11 and heart.12
FGF23 levels gradually increase in parallel with declining
renal function.13 High circulating FGF23, both in individuals
with end-stage renal disease receiving dialysis treatment
and in patients with moderate impairment of the glomerular
filtration rate (GFR), is associated with an increased
risk for multiple adverse outcomes, including mortality and
CKD progression.14–16 Yet the relationship between FGF23
and cardiovascular events in the general population has not
been investigated.
We hypothesized that a higher FGF23 level, also in the
concentration range not previously considered to be of
pathophysiological relevance, predicts cardiovascular events.
Accordingly, the aim of this study was to investigate the
relationship between FGF23 and cardiovascular events in a
community-based cohort of elderly men.
c l in i ca l inves t iga t ion http://www.kidney-international.org
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RESULTS
Baseline characteristics for all participants and according to
quintiles of FGF23 are shown in Table 1. During follow-up
(median 9.7 years, range 0.3–12.9 years), 110 participants
died of cardiovascular causes (incidence rate 2.07/100
person-years at risk). The incidence rates for cardiovascular
and noncardiovascular mortality over FGF23 quintiles are
shown in Table 2.
In our primary continuous models, higher FGF23 was
associated with higher risk for cardiovascular mortality after
adjustment for age and established cardiovascular risk factors
(models A–B, Table 3). In multicategory and threshold
models, participants in the highest quintile of FGF23 were
at higher risk for cardiovascular mortality compared with
participants in quintile 1 and quintiles 1–4, respectively
(Model A–B, Table 3). The association between FGF23 and
cardiovascular mortality was attenuated but remained
statistically significant after further adjustments for GFR
(model C, Table 3). In secondary models, the associations
remained unaltered after the addition of albuminuria, left
ventricular hypertrophy (assessed by electrocardiogram), and
markers of inflammation and oxidative stress to multi-
variable model C (Model D, Table 3) or when replacing the
hypertension treatment variable with data on specific
antihypertensive medication ((angiotensin-converting en-
zyme inhibitors/angiotensin 2 receptor blockers, alpha-
blockers, beta-blockers, calcium antagonists, or diuretics),
Model B hazard ratio (HR) per s.d. increase 1.30, 95% CI
1.11–1.53, P¼ 0.002).
In crude models, FGF23 was also associated with all-cause
mortality, albeit weaker than for cardiovascular mortality
(Table 3). Further, after multivariate adjustment (Model C),
this relationship was nonsignificant in both continuous and
threshold models, and the association between FGF23 and
noncardiovascular mortality was not significant in any model
(data not shown). Collectively, this suggests that FGF23
primarily is associated with cardiovascular mortality and
that its relationship with all-cause mortality is driven by
cardiovascular deaths.
Examination of regression splines suggested that the
increase in risk is log-linear where the highest increase in
HR was seen in FGF23 levels above quintile 5 (Figure 1). The
cumulative incidence of cardiovascular mortality in quintile 5
vs. quintile 1–4 is shown in Figure 2.
As seen in Table 4, participants with low GFR (o60ml/
min), microalbuminuria (43mg/ml), and high FGF23
defined as within the highest quintile (460 pg/ml) had a
more than sixfold increase in risk for cardiovascular morta-
lity, compared with participants with GFR 460ml/min,
Table 1 | Baseline characteristics of the ULSAM cohort and by quintiles (Q1–Q5) of FGF23
Variable All Q1 Q2 Q3 Q4 Q5
Number of subjects 727 162 135 141 150 139
Age (years) 77.6 (0.76) 77.6 (0.66) 77.5 (0.76) 77.6 (0.80) 77.6 (0.79) 77.6 (0.82)
Serum FGF23 (pg/ml) 44 (9–162) 28 (9–33) 37 (34–40) 44 (41–47) 53 (48–59) 70 (60–162)
Glomerular filtration rate (ml/min per 1.73m2) 74 (17) 81 (16) 78 (14) 73 (15) 72 (13) 62 (18)
Urinary albumin/creatinine ratio (mg/mmol) 3.8 (14) 2.3 (7.4) 2.3 (4.3) 3.7 (16) 3.5 (8.6) 7.8 (25)
Body mass index (kg/m2) 26 (3.5) 26 (3.3) 26 (3.8) 27 (3.5) 26 (3.4) 27 (3.2)
Serum total cholesterol (mg/dl) 5.4 (1.0) 5.2 (0.98) 5.5 (1.1) 5.4 (0.91) 5.4 (0.94) 5.6 (0.97)
Serum HDL cholesterol (mg/dl) 1.3 (0.32) 1.3 (0.34) 1.3 (0.31) 1.3 (0.30) 1.3 (0.33) 1.3 (0.33)
Systolic blood pressure (mmHg) 151 (20) 148 (20) 150 (20) 151 (21) 152 (19) 151 (22)
Diabetes 97 (13%) 24 (15%) 12 (9%) 15 (11%) 27 (18%) 19 (14%)
Smoking—n (%) 57 (8) 10 (6) 16 (12) 14 (10) 6 (4) 11 (8)
Previous cardiovascular disease—n (%) 126 (27) 35 (22) 28 (21) 39 (28) 42 (28) 52 (37)
Lipid-lowering treatment—n (%) 125 (18) 28 (17) 21 (16) 22 (16) 23 (15) 31 (15)
Aspirin (%) 205 (28%) 34 (21%) 32 (24%) 44 (31%) 45 (30%) 50 (36%)
Antihypertensive treatment—n (%) 348 (48) 60 (37) 58 (43) 73 (42) 71 (47) 86 (62)
ECG-LVH 228 (31%) 44 (27%) 48 (36%) 45 (32%) 41 (27%) 50 (36%)
Serum interleukin-6 (ng/l) 3.9 (2.6) 4.0 (2.8) 3.6 (2.7) 3.6 (2.4) 3.8 (2.5) 4.2 (2.7)
Serum C-reactive protein (mg/l) 3.9 (7.0) 3.9 (7.0) 3.5 (5.8) 3.1 (3.7) 4.7 (10.4) 4.4 (6.2)
Urinary F2 isoprostane (pmol/mmol) 0.20 (0.1) 0.21 (0.1) 0.20 (0.09) 0.19 (0.08) 0.21 (0.12) 0.19 (0.09)
Urinary 15-keto-dihydro-prostaglandin F-2a (pmol/mmol) 0.23 (0.2) 0.36 (0.20) 0.32 (0.17) 0.31 (0.15) 0.32 (0.19) 0.31 (0.19)
Abbreviations: ECG, electro cardiogram; FGF23, fibroblast growth factor-23; GFR, glomerular filtration rate; HDL, high-density lipoprotein; LVH, left ventricle hypertrophy.
Data are mean±s.d. or median (range) for continuous variables as appropriate and n (%) for categorical variables.
Table 2 | The association between serum FGF23 and mortality
in the ULSAM cohort: incidence rates (per 1000 person-years
at risk) for all-cause mortality and cardiovascular mortality
















48/162 39 (29–52) 19/162 15 (10–24)
Quintile 2
(34–40pg/ml)
47/136 46 (34–61) 20/136 20 (13–30)
Quintile 3
(41–47pg/ml)
43/141 41 (31–56) 17/141 16 (10–26)
Quintile 4
(48–59pg/ml)
50/149 45 (34–59) 21/149 19 (12–29)
Quintile 5
(X60pg/ml)
64/139 70 (55–90) 33/139 36 (26–51)
Abbreviations: CI, confidence interval; FGF23, fibroblast growth factor-23.
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no albuminuria, and FGF23o60 pg/ml after adjustment for
cardiovascular risk factors.
A statistically significant effect modification by GFR level
was observed (P¼ 0.03). Thus, we performed stratified
analyses in participants above versus below GFR 60ml/min.
The association between FGF23 and cardiovascular mortality
was higher in participants with a GFR below 60ml/min
(number of events/numbers at risk 39/146, Model C HR per
s.d. increment of FGF23 1.37; 95% CI 1.02–1.85; P¼ 0.04),
compared with those with a GFR above 60ml/min (number
of events/numbers at risk 71/581, Model C HR per s.d.
increment of FGF23 0.95; 95% CI 0.70–1.30; P¼ 0.76). We
found no evidence for effect modification by gender, systolic
blood pressure, hypertension treatment (both as a composite
variable or when investigating specific antihypertensive
medication), high-density lipoprotein cholesterol, total
cholesterol, lipid-lowering medication, smoking, diabetes,
prevalent cardiovascular disease, body mass index, or
C-reactive protein (P40.10 for all).
DISCUSSION
In this study, we hypothesized that FGF23 would be
associated with an increased risk for cardiovascular events
in community-dwelling adults. Indeed, we confirm that
higher FGF23, also in the concentration range previously not
considered to be of pathophysiological relevance, is asso-
ciated with increased risk for cardiovascular mortality
independent of established cardiovascular risk factors. The
strength of the association between FGF23 and cardiovascular
mortality remained significant but was attenuated after
adjustment for GFR, and stratified analysis revealed that
FGF23 was not associated with cardiovascular mortality in
individuals with GFR above 60ml/min. Thus, our commu-
nity-based data suggest that the potential clinical relevance of
FGF23 is restricted to CKD patients. Interestingly, partici-
pants who had a combination of high FGF23, low GFR, and
micro-/macro-albuminuria had substantially increased car-
diovascular risk, indicating that these three different aspects
of kidney pathology portray independent and additive
prognostic information.
The present study corroborates with other reports
proposing FGF23 as a cardiovascular risk factor. In selected
Table 3 | The association between serum FGF23, and cardiovascular and all-cause mortality in the ULSAM cohort: multivariable
Cox regression
FGF23 Cardiovascular mortality All-cause mortality






















Referent Referent Referent Referent Referent Referent Referent Referent
Quintile 2
(34–40pg/ml)
1.27 (0.68–2.39) 1.31 (0.70–2.49) 1.27 (0.67–2.71) 1.30 (0.65–2.60) 1.21 (0.81–1.81) 1.24 (0.83–1.87) 1.24 (0.82–1.86) 1.36 (0.87–2.13)
Quintile 3
(41–47pg/ml)
1.08 (0.56–2.08) 0.99 (0.51–1.94) 0.86 (0.45–1.70) 0.73 (0.34–1.57) 1.08 (0.72–1.63) 1.07 (0.70–1.63) 0.99 (0.65–1.52) 0.99 (0.62–1.59)
Quintile 4
(48–59pg/ml)
1.23 (0.66–2.29) 1.10 (0.59–2.06) 0.97 (0.52–1.82) 0.91 (0.47–1.78) 1.14 (0.77–1.70) 1.11 (0.74–1.65) 1.03 (0.68–1.54) 1.12 (0.72–1.73)
Quintile 5
(X60pg/ml)




Referent Referent Referent Referent Referent Referent Referent Referent
Quintile 5
(X60pg/ml)
2.12 (1.41–3.19)*** 2.04 (1.34–3.12)*** 1.59 (1.01–2.50)* 1.64 (0.96–2.80) 1.69 (1.27–2.24)*** 1.75 (1.30–2.34)*** 1.47 (1.08–2.01)* 1.24 (0.87–1.78)*
Abbreviations: CI, confidence interval; FGF23, fibroblast growth factor-23.
Primary models: Model A adjusted for age; Model B adjusted for age and established cardiovascular risk factors (cardiovascular disease at baseline, antihypertensive
treatment, lipid-lowering treatment, current smoking, diabetes, systolic blood pressure, body mass index, total cholesterol, and high-density lipoprotein cholesterol); Model
C adjusted for all covariates in Model B and glomerular filtration rate; and secondary models: Model D adjusted for all covariates in Model C and, left ventricular
hypertrophy, albuminuria, and markers of inflammation and antioxidative stress.
*Po0.05; **Po0.01; ***Po0.001.
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Figure 1 | Spline curve showing the relationship between
fibroblast growth factor-23 (FGF23) and risk of cardiovascular
mortality in the ULSAM cohort. Q, quintile.
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patient groups, FGF23 is associated with all-cause mortality
in dialysis patients,15,17,18 renal transplant recipients,19 and
in pre-dialysis CKD patients.16,20,21 Further, FGF23 was
independently associated with an increased risk for
cardiovascular mortality in individuals free of CKD but
with manifest coronary artery disease.22 However, this is the
first study to demonstrate an association between FGF23 and
cardiovascular mortality in community-dwelling adults.
There are several plausible mechanisms underlying our
epidemiological findings. FGF23 is a phosphaturic hormone
and gradually rises in CKD to prevent the onset of hyperpho-
sphatemia in the face of increased bone turnover and a
progressive decline in functional renal mass.23 Hence, FGF23
was proposed to be a surrogate marker of time-averaged
phosphate exposure, a measure that more adequately portrays
the phosphate burden and risk for development of vascular
calcification compared with the measurement of serum
phosphate alone.15 FGF23 is also a potent inhibitor of
vitamin D metabolism and PTH secretion, presenting the
possibility that FGF23 to some extent reflects the risk exposure
associated with vitamin D deficiency and hyperpara-
thyroidism. However, the strength of FGF23 association with
adverse outcomes was not attenuated by adjustments for these
confounders of mineral metabolism in other studies,15,16,19
indicating that other pathways are involved.
A current debate entails the possibility that the vascular
system may be a target organ for FGF23, which can be
assumed by the presence of the FGF23 obligatory coreceptor
Klotho in vascular smooth muscle cells.11 It remains to be
elucidated whether FGF23 is a cause or consequence of
vascular damage. Given that FGF23 is a mineralization
inhibitor in bone,24,25 it may exert similar effects in the
vascular system, thus representing a defense mechanism
against vascular calcification found in a majority of patients
with advanced CKD. This hypothesis is favored by recent
experimental data.11 Additional support for vascular effects
of FGF23 derives from cross-sectional studies in CKD
patients and healthy individuals, in which FGF23 has been
associated with dynamic measurements of vascular
function,26,27 as well as with the degree of calcification
and/or atherosclerosis28–30 in peripheral arteries, aorta, and
coronary arteries.
Importantly, FGF23 was reported to directly promote
cardiomyocyte growth in vitro and to induce left ventricular
hypertrophy in mice with normal kidney function.12 In
humans, FGF23 levels have been linked to increased risk
for the presence of left ventricular hypertrophy and left
ventricular mass in CKD patients and in individuals free of
CKD.31–33 Although we adjusted for the presence of left
ventricular hypertrophy in our multivariate models, this
remains a biologically plausible pathway, especially as
electrocardiogram is not an ideal tool for the determination
of left ventricular hypertrophy.
The observational evidence linking FGF23 to mortality
and cardiovascular disease is growing, yet it is currently
unknown whether FGF23 is a modifiable risk factor.
Phosphate-binding therapy, especially non-calcium-based
binders, have proven effective in terms of reducing circulat-
ing FGF23 in CKD stage 3–4 when FGF23 levels are only
mildly elevated compared with individuals free of CKD.34,35
It remains elusive whether such therapy translates into a
reduction in cardiovascular events, and larger observational
and interventional trials would be required to define the
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Figure 2 | Curve showing the cumulative incidence of
cardiovascular mortality in the ULSAM cohort by above
versus below the fifth quintile of fibroblast growth factor-23.
Log-rank P¼ 0.0002. Q, quintile.
Table 4 |Data portraying the interplay between the number of abnormal kidney components: FGF23, GFR, and albuminuria
and the risk for cardiovascular mortality in ULSAM in Cox proportional regression models







hazard ratio (95% CI)
Full model hazard
ratio (95% CI)
Normal GFR, normo-albuminuria, and FGF23o60pg/ml 36/375 Referent Referent Referent
One non-normal component 42/244 1.86 (1.19–2.91)** 1.66 (1.05–2.61)* 1.41 (0.84–2.36)
Two non-normal components 19/81 2.92 (1.67–5.10)*** 2.38 (1.33–4.26)** 2.74 (1.48–5.10)**
Three non-normal components 12/28 7.96 (4.17–15.20)*** 6.47 (3.28–12.74)*** 5.40 (2.37–12.31)***
Abbreviations: CI, confidence interval; CV, cardiovascular; FGF23, fibroblast growth factor-23; GFR, glomerular filtration rate.
Normal GFR (X60ml/min), normo-albuminuria (o3mg/ml), and FGF23 (o60pg/ml). CV risk factors (CV disease at baseline, antihypertensive treatment, lipid-lowering
treatment, current smoking, diabetes, systolic blood pressure, body mass index, total cholesterol, and high-density lipoprotein cholesterol). The full model was adjusted for
all covariates in the CV risk factor-adjusted model, left ventricular hypertrophy, and markers of inflammation and antioxidative stress.
*Po0.05; **Po0.01; ***Po0.001.
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FGF23 becomes elevated in CKD because of the yet unknown
pathological factor(s) released from the failing kidney and
that such a factor would be the ‘true’ treatment target rather
than primary reduction of FGF23 levels.
There is an ongoing debate regarding whether routine
FGF23 measurements should be implemented in standard
clinical care of patients with impaired kidney function as part
of a risk assessment regime. FGF23 has consistently been
shown to predict negative outcomes across the spectrum of
CKD, and these findings are now extended to the general
population with normal FGF23 levels but mild reductions in
GFR. Larger clinical studies are warranted to identify relevant
thresholds of FGF23 for predicting clinically meaningful
outcomes.
Strengths of this study include the longitudinal study
design, the detailed characterization of the study participants,
and high quality of population registers in Sweden, allowing
us to reach the whole population and link each individual to
The National Cause of Death Register,36 which have been
shown to be in almost complete accord (99.8%) with patient
journals from local hospitals.37
There are also some limitations to this study that needs
mentioning. The cohort consists of elderly Caucasian men,
which is why extrapolations of our findings to other age
groups, ethnicities, and women should be done with caution.
This is relevant because blacks and Hispanics have lower
circulating FGF23 but higher phosphate levels than whites.15
Similarly, estrogens are known to influence FGF23-
modulating factors, including PTH, 1,25(OH)2D, and
phosphate levels,38,39 although a previous study did not
show any gender difference for serum FGF23 in elderly men
and women free of CKD.26
Unfortunately, we were also unable to adjust for potential
confounders of mineral metabolism, including dietary intake
of phosphate and vitamin D and serum parameters such as
calcium, phosphate, PTH, and 25(OH)D. Previous reports
support that adjustment for these variables does not alter the
association between FGF23 and mortality, and some studies
rather suggest a strengthened relationship when taking these
variables into account.15,16,19 Conversely, adjustment for
FGF23 blunted the established association between PTH
and mortality in renal transplant recipients,19 supporting the
fact that FGF23 is in the casual pathway.
Another potential confounder is aldosterone, as PTH is a
regulator of both FGF23 in bone40 and aldosterone in adrenal
glands;41 hence, adjustment for aldosterone would have
been of interest to investigate whether activation of the
renin–angiotensin–aldosterone system modulates the rela-
tionship between FGF23 and cardiovascular mortality.
Additional studies are warranted to ultimately prove an
independent association between FGF23 and cardiovascular
mortality.
In summary, FGF23 is an independent predictor of
cardiovascular mortality in the community-dwelling adults,




The ULSAM study was initiated in 1970. All 50-year-old men, born
in 1920–1924 and living in Uppsala, Sweden, were invited to a health
survey, focusing at identifying cardiovascular risk factors42
(described in detail on http://www.pubcare.uu.se/ULSAM). These
analyses are based on the fourth examination cycle of ULSAM, when
participants were B77 years old (1998–2001). Of 1398 men who
were invited, 838 (60%) participated. Of these, 111 were excluded
owing to missing data on FGF23 (n¼ 77) or covariates (n¼ 34),
leaving 727 participants as the present study sample. All participants
gave written informed consent, and the Ethics Committee of
Uppsala University approved the study protocols.
Baseline investigations
The investigations were carried out using standardized methods,
including anthropometrical measurements, blood pressure, blood
sampling, and questionnaires regarding socioeconomic status,
medical history, smoking habits, medication, and physical activity
level.42 Venous blood samples were drawn in the morning after an
overnight fast and stored at –701C until analysis. Serum FGF23
was measured using an intact FGF23 ELISA (Kainos Laboratories,
Tokyo, Japan). The intra-assay coefficient of variation was o4%.
Inflammatory markers and cystatin C were measured as previously
described in ULSAM.43 GFR was calculated from serum cystatin C
by using the formula y¼ 79.901CystC 1.4389, which has been
shown to be closely correlated with iohexol clearance.44
Electrographic left ventricular hypertrophy was defined as
high-amplitude R waves according to the revised Minnesota
code45 together with a left ventricular strain pattern.46 Diabetes
mellitus was diagnosed as fasting plasma glucose X7.0mmol/l
(X126mg/dl), or the use of antidiabetic medication. Prevalent
cardiovascular disease at baseline was defined as a history of
ischemic heart disease or cerebrovascular disease, or Q, QS
complexes, or left bundle-branch block in baseline ECG.
Follow-up and end point definitions
The Swedish Cause-of-Death register was used to define cardiovas-
cular mortality (ICD-10 codes I00–I99). End of follow-up was 31
December 2008.
Statistical analysis
The relationship between serum FGF23 and cardiovascular mortal-
ity was investigated using Cox regression models:
(A) Age-adjusted; (B) Cardiovascular risk factor model (age, sex,
systolic blood pressure, diabetes, smoking, body mass index, total
cholesterol, high-density lipoprotein cholesterol, antihypertensive
treatment, lipid-lowering treatment, and prevalent cardiovascular
disease); (C) Cardiovascular risk factors (in Model B) and GFR.
In primary analyses, we modeled FGF23 as a continuous variable
(expressed as 1-s.d. increase of serum FGF23).
We performed secondary analyses in which the following
variables were added to model C: urinary albumin/creatinine ratio,
electrographic left ventricular hypertrophy, C-reactive protein,
interleukin-6, serum amyloid A, urinary 15-keto-dihydro-PGF2a
(reflecting COX-mediated inflammation), and urinary F2 isopros-
tanes (reflecting oxidative stress) (Model D). Moreover, we
replaced the antihypertensive treatment variable in the model B
with the use of angiotensin-converting enzyme inihibitors/angio-
tensin 2 receptor blockers, alpha-blockers, beta-blockers, calcium
164 Kidney International (2012) 83, 160–166
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antagonists, or diuretics. In secondary analyses, we further
used multicategory models comparing risk in FGF23 quintiles 2,
3, 4, and 5 with that in quintile 1, and threshold models (quintile 5
vs. quintile 1–4).
Tests for effect modifications by microalbuminuria, GFR, and
prevalent cardiovascular disease at baseline were performed by invoking
multiplicative interaction terms in Model B. To gain additional insights
into potential nonlinearity of the associations, we examined the Cox
regression models using penalized splines. Proportional hazards
assumptions were confirmed by Schoenfeld’s tests.
To evaluate the interplay between FGF23 and other aspects of
kidney pathology in the risk of cardiovascular mortality, we divided
the participants in the following four groups:
(1) Participants with normal GFR (X60ml/min), normo-albumi-
nuria (o3mg/ml), and FGF23 o60 pg/ml.
(2) Participants with any one abnormality of these parameters.
(3) Participants with any two abnormalities of these parameters.
(4) Participants with all three parameters being abnormal.
A two-sided P-value o0.05 was regarded as significant in all
analyses. The statistical software package STATA 10.0 (Stata Corp,
College Station, TX) was used for all analyses.
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